Thailand ATTR-CM patient registry
Part of Heart & circulation clinical trials.
This registry collects information from people with ATTR-CM, a condition where abnormal protein builds up in the heart. By joining, you help researchers learn more about the disease and improve future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM), even if you have no symptoms.
- Your heart shows signs of the disease, confirmed by a heart scan, biopsy, or MRI.
- You do not have another type of amyloidosis (like light chain amyloidosis) or secondary amyloidosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called Coramitug for people with heart failure due to ATTR amyloidosis, a condition where abnormal proteins build up in the heart. The study aims to see if Coramitug can improve heart function and quality of life.
This study follows people with a heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM) who are starting treatment with acoramidis. It aims to see how well the medicine works in everyday medical practice.
This study is testing a medication called acoramidis for people with a heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM). It aims to see how well the treatment works in a real-world setting in France.
This trial tests a smartphone app that lets you track symptoms and share them with your care team between visits. The goal is to see if remote monitoring is practical and helpful for people with ATTR-CM.
This study aims to better understand a type of heart disease called wild-type transthyretin amyloid cardiomyopathy (wtATTR-CM). It will compare people with this condition to a control group without known heart disease to identify key features.
This study looks at ATTR cardiac amyloidosis (a condition caused by an inherited protein change) in people who have the disease or carry the gene. It may help researchers learn how ATTR affects the heart and how care can be improved.
Hear when a new Transthyretin Amyloid Cardiomyopathy (ATTR-CM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.